4.8 Article

The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15

期刊

IMMUNITY
卷 44, 期 1, 页码 103-115

出版社

CELL PRESS
DOI: 10.1016/j.immuni.2015.12.007

关键词

-

资金

  1. National Health and Medical Research Council (NH&MRC) of Australia [1027472, 1047903, 1016647, 1049407, 1066770, 1057852]
  2. National Health and Medical Research Council of Australia [GNT0461276, 1058344, 545952]
  3. Australian Research Council
  4. Cancer Australia
  5. Menzies Foundation
  6. Leukaemia Foundation scholarship
  7. European Research Council (THINK Advanced Grant)
  8. INSERM
  9. CNRS
  10. Aix Marseille
  11. Boehringer Ingelheim
  12. ERC Advanced Grant (Lymphocyte Control) from the European Community's Seventh Framework Program [291740]
  13. [628623]
  14. Grants-in-Aid for Scientific Research [15K19547] Funding Source: KAKEN
  15. European Research Council (ERC) [291740] Funding Source: European Research Council (ERC)

向作者/读者索取更多资源

The inhibitor of DNA binding 2 (Id2) is essential for natural killer (NK) cell development with its canonical role being to antagonize E-protein function and alternate lineage fate. Here we have identified a key role for Id2 in regulating interleukin-15 (IL-15) receptor signaling and homeostasis of NK cells by repressing multiple E-protein target genes including Socs3. Id2 deletion in mature NK cells was incompatible with their homeostasis due to impaired IL-15 receptor signaling and metabolic function and this could be rescued by strong IL-15 receptor stimulation or genetic ablation of Socs3. During NK cell maturation, we observed an inverse correlation between E-protein target genes and Id2. These results shift the current paradigm on the role of ID2, indicating that it is required not only to antagonize E-proteins during NK cell commitment, but constantly required to titrate E-protein activity to regulate NK cell fitness and responsiveness to IL-15.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据